Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Individual Case Safety Reports Analysis for Patients with Diabetes Mellitus on Insulin in Africa and the Middle East

Author(s): Charity R.N. Mlotshwa*, Johanita R. Burger, Martine Vorster, Dorcas M. Rakumakoe and Marike Cockeran

Volume 17, Issue 3, 2022

Published on: 01 February, 2022

Page: [225 - 234] Pages: 10

DOI: 10.2174/1574886316666211108103301

Price: $65

Abstract

Background: The growing numbers of patients with diabetes mellitus in Africa and the Middle East on antidiabetic therapies necessitate an understanding of adverse event (AE) reporting in these regions.

Objective: The aim of the study was to provide an AE reporting overview in patients using insulin in Africa and the Middle East by characterizing and comparing individual case safety reports (ICSRs) features.

Methods: The cross-sectional study analyzed ICSR data from a global pharmaceutical company’s pharmacovigilance database for January to December 2018 to describe and compare patient demographics, report sources, reporter types, ICSR seriousness, suspect products, indication for insulin use and AE preferred terms, by country.

Results: Overall 7076 ICSRs were analyzed, 63.6% from the Middle East. Most ICSRs were nonserious (91.5%), from solicited sources (83.5%), and reported by consumers (70.7%). Patients from the Middle East were, on average, 34.2 years of age, had gestational diabetes mellitus as indication (64.3%), insulin detemir as suspect product (76.5%), and exposure during pregnancy as AE preferred term (89.1%). Patients from Africa were 48.1 years old on average, a higher proportion of type 2 diabetes mellitus was observed (52.2%), human insulin was the suspect product (51.6%), and blood glucose increased the AE preferred term (23.1%). Few macrovascular and microvascular complications were reported (< 1% in both regions). Associations between the region and patient age, gender, report sources, reporter types, indications for insulin use, suspect products, and AE preferred term were significant (p < 0.001).

Conclusion: ICSRs features were region-specific and dependent on patient age, gender, report sources, reporter types, suspect products, and AE preferred terms.

Keywords: Diabetes mellitus, adverse event reporting, database, insulin, ICSR, suspect products, blood glucose.

« Previous Next »
Graphical Abstract

[1]
Alawadi F, Abusnana S, Afandi B, et al. Emirates diabetes society consensus guidelines for the management of type 2 diabetes mellitus. Dubai Diabetes Endocrinol J 2020; 2020: e1-e20.
[http://dx.doi.org/10.1159/000506508]
[2]
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care 2019; 42(Suppl. 1): S90-S102.
[http://dx.doi.org/10.2337/dc19-S009] [PMID: 30559235]
[3]
Ogunbanjo GA. Glucose control: insulin therapy. S Afr Fam Pract 2018; 60(2): 5-7.
[http://dx.doi.org/10.4102/safp.v60i4.4904]
[4]
Thrasher J. Pharmacologic management of type 2 diabetes mellitus: Available therapies. Am J Med 2017; 130(6S): S4-S17.
[http://dx.doi.org/10.1016/j.amjmed.2017.04.004] [PMID: 28526182]
[5]
Feng Y, Yang H. Metformin - a potentially effective drug for gestational diabetes mellitus: A systematic review and meta-analysis. J Matern Fetal Neonatal Med 2017; 30(15): 1874-81.
[http://dx.doi.org/10.1080/14767058.2016.1228061] [PMID: 27549367]
[6]
Amiel SA, Aschner P, Childs B, et al. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol 2019; 7(5): 385-96.
[http://dx.doi.org/10.1016/S2213-8587(18)30315-2] [PMID: 30926258]
[7]
Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done? Diabetes Obes Metab 2017; 19(12): 1655-68.
[http://dx.doi.org/10.1111/dom.13009] [PMID: 28509408]
[8]
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet 2017; 389(10085): 2239-51.
[http://dx.doi.org/10.1016/S0140-6736(17)30058-2] [PMID: 28190580]
[9]
Deng N, Zhang X, Zhao F, Wang Y, He H. Prevalence of lipohypertrophy in insulin-treated diabetes patients: A systematic review and meta-analysis. J Diabetes Investig 2017; 9(3): 536-43.
[http://dx.doi.org/10.1111/jdi.12742] [PMID: 28862814]
[10]
Higbea AM, Duval C, Chastain LM, Chae J. Weight effects of antidiabetic agents. Expert Rev Endocrinol Metab 2017; 12(6): 441-9.
[http://dx.doi.org/10.1080/17446651.2017.1395694] [PMID: 30063431]
[11]
Jedlowski PM, Te CH, Segal RJ, Fazel MT. Cutaneous adverse effects of diabetes mellitus medications and medical devices: A review. Am J Clin Dermatol 2019; 20(1): 97-114.
[http://dx.doi.org/10.1007/s40257-018-0400-7] [PMID: 30361953]
[12]
Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi Khalil C. Macrovascular complications in patients with diabetes and prediabetes. BioMed Res Int 2017; 2017: 7839101.
[http://dx.doi.org/10.1155/2017/7839101] [PMID: 29238721]
[13]
Antwi-Bafour S, Hammond S, Adjei JK, Kyeremeh R, Martin-Odoom A, Ekem I. A case-control study of prevalence of anemia among patients with type 2 diabetes. J Med Case Reports 2016; 10(1): 110.
[http://dx.doi.org/10.1186/s13256-016-0889-4] [PMID: 27142617]
[14]
Piloya-Were T, Sunni M, Ogle GD, Moran A. Childhood diabetes in africa. Curr Opin Endocrinol Diabetes Obes 2016; 23(4): 306-11.
[http://dx.doi.org/10.1097/MED.0000000000000262] [PMID: 27228228]
[15]
Tinker SC, Gilboa SM, Moore CA, et al. Specific birth defects in pregnancies of women with diabetes: National Birth Defects Prevention Study, 1997-2011. Am J Obstet Gynecol 2020; 222(2): 176.e1-176.e11.
[http://dx.doi.org/10.1016/j.ajog.2019.08.028] [PMID: 31454511]
[16]
Gabriel MH, Atkins D, Chisholm L, Noblin A. Adverse events among patients with diabetes and ambulatory practice characteristics: Evidence from a nationally representative survey. SAGE Open 2018; 8(2)
[http://dx.doi.org/10.1177/2158244018782732]
[17]
Choda G, Rao G. Diabetes related clinical complications: novel approaches for diagnosis and management. J Clin Cardiol Diagn 2019; 2(2): 1-8.
[18]
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018; 14(2): 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID: 29219149]
[19]
Razavi-Nematollahi L, Ismail-Beigi F. Adverse effects of glycemia-lowering medications in type 2 diabetes. Curr Diab Rep 2019; 19(11): 132.
[http://dx.doi.org/10.1007/s11892-019-1266-7] [PMID: 31748838]
[20]
Bhorat I, Pillay M, Reddy T. Assessment of the Fetal myocardial performance index in well-controlled gestational diabetics and to determine whether it is predictive of adverse perinatal outcome. Pediatr Cardiol 2019; 40(7): 1460-7.
[http://dx.doi.org/10.1007/s00246-019-02158-4] [PMID: 31324952]
[21]
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 107843.
[http://dx.doi.org/10.1016/j.diabres.2019.107843] [PMID: 31518657]
[22]
Mohan V, Khunti K, Chan SP, et al. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther 2020; 11(1): 15-35.
[http://dx.doi.org/10.1007/s13300-019-00733-9] [PMID: 31773420]
[23]
International Diabetes Federation. IDF Diabetes Atlas 2019 Ninth Edition. 2019. Available from:https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf#page=42&zoom=auto (Accessed:25 October 2020).
[24]
European Medical Agency. EuDRA CT Glossary 2019. Available from:https://eudract.ema.europa.eu/help/Content/Glossary.htm (Accessed:22 September 2020).
[25]
Wallace S, Myles PS, Zeps N, Zalcberg JR. Serious adverse event reporting in investigator-initiated clinical trials. Med J Aust 2016; 204(6): 231-3.
[http://dx.doi.org/10.5694/mja15.01007] [PMID: 27031396]
[26]
Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 2012; 141(1): 2-18.
[http://dx.doi.org/10.1037/a0024338] [PMID: 21823805]
[27]
Jokinen JD, Walley RJ, Colopy MW, Hilzinger TS, Verdru P. Pooling different safety data sources: impact of combining solicited and spontaneous reports on signal detection in pharmacovigilance. Drug Saf 2019; 42(10): 1191-8.
[http://dx.doi.org/10.1007/s40264-019-00843-0] [PMID: 31190237]
[28]
Jokinen J, Bertin D, Donzanti B, et al. Industry assessment of the contribution of patient support programs, market research programs, and social media to patient safety. Ther Innov Regul Sci 2019; 53(6): 736-45.
[http://dx.doi.org/10.1177/2168479019877384] [PMID: 31684774]
[29]
Chow CK, Ramasundarahettige C, Hu W, et al. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: A prospective epidemiological study. Lancet Diabetes Endocrinol 2018; 6(10): 798-808.
[http://dx.doi.org/10.1016/S2213-8587(18)30233-X] [PMID: 30170949]
[30]
Avong YK, Jatau B, Gurumnaan R, et al. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study. PLoS One 2018; 13(8): e0200810.
[http://dx.doi.org/10.1371/journal.pone.0200810] [PMID: 30133453]
[31]
Akbarzadeh A, Salehi A, Molavi Vardanjani H, et al. Epidemiology of adult diabetes mellitus and its correlates in Pars cohort study in southern Iran. Arch Iran Med 2019; 22(11): 633-9.
[PMID: 31823628]
[32]
Chivese T, Werfalli MM, Magodoro I, et al. Prevalence of type 2 diabetes mellitus in women of childbearing age in Africa during 2000-2016: A systematic review and meta-analysis. BMJ Open 2019; 9(5): e024345.
[http://dx.doi.org/10.1136/bmjopen-2018-024345] [PMID: 31122965]
[33]
Mirzaei M, Rahmaninan M, Mirzaei M, Nadjarzadeh A, Dehghani Tafti AA. Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study. BMC Public Health 2020; 20(1): 166.
[http://dx.doi.org/10.1186/s12889-020-8267-y] [PMID: 32013917]
[34]
Al-Rifai RH, Majeed M, Qambar MA, Ibrahim A, AlYammahi KM, Aziz F. Type 2 diabetes and pre-diabetes mellitus: A systematic review and meta-analysis of prevalence studies in women of childbearing age in the Middle East and North Africa, 2000-2018. Syst Rev 2019; 8(1): 268.
[http://dx.doi.org/10.1186/s13643-019-1187-1] [PMID: 31703716]
[35]
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health 2020; 10(1): 107-11.
[http://dx.doi.org/10.2991/jegh.k.191028.001] [PMID: 32175717]
[36]
Al-Ghamdi AH, Fureeh AA. Prevalence and clinical presentation at the onset of type 1 diabetes mellitus among children and adolescents in AL-Baha region, Saudi Arabia. J Pediatr Endocrinol Metab 2018; 31(3): 269-73.
[http://dx.doi.org/10.1515/jpem-2017-0059] [PMID: 29537213]
[37]
Shaltout AA, Wake D, Thanaraj TA, et al. Incidence of type 1 diabetes has doubled in Kuwaiti children 0-14 years over the last 20 years. Pediatr Diabetes 2017; 18(8): 761-6.
[http://dx.doi.org/10.1111/pedi.12480] [PMID: 27981709]
[38]
Atun R, Davies JI, Gale EAM, et al. Diabetes in sub-Saharan Africa: From clinical care to health policy. Lancet Diabetes Endocrinol 2017; 5(8): 622-67.
[http://dx.doi.org/10.1016/S2213-8587(17)30181-X] [PMID: 28688818]
[39]
Jasem D, Majaliwa ES, Ramaiya K, Najem S, Swai ABM, Ludvigsson J. Incidence, prevalence and clinical manifestations at onset of juvenile diabetes in Tanzania. Diabetes Res Clin Pract 2019; 156: 107817.
[http://dx.doi.org/10.1016/j.diabres.2019.107817] [PMID: 31425767]
[40]
Seyfarth J, Sarfo-Kantanka O, Rosenbauer J, Phillips RO, Jacobsen M. Type-1 diabetes onset age and sex differences between Ghanaian and German urban populations. J Diabetes 2019; 11(12): 1002-4.
[http://dx.doi.org/10.1111/1753-0407.12978] [PMID: 31420945]
[41]
de Vries ST, Denig P, Ekhart C, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. Br J Clin Pharmacol 2019; 85(7): 1507-15.
[http://dx.doi.org/10.1111/bcp.13923] [PMID: 30941789]
[42]
O’ Donovan B, Rodgers RM, Cox AR, Krska J. Making medicines safer: Analysis of patient reports to the UK’s Yellow Card Scheme. Expert Opin Drug Saf 2019; 18(12): 1237-43.
[http://dx.doi.org/10.1080/14740338.2019.1669559] [PMID: 31538503]
[43]
Rydberg DM, Mejyr S, Loikas D, Schenck-Gustafsson K, von Euler M, Malmström RE. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. Eur J Clin Pharmacol 2018; 74(9): 1165-73.
[http://dx.doi.org/10.1007/s00228-018-2480-y] [PMID: 29804162]
[44]
Ajlouni K, Batieha A, Jaddou H, et al. Time trends in diabetes mellitus in Jordan between 1994 and 2017. Diabet Med 2019; 36(9): 1176-82.
[http://dx.doi.org/10.1111/dme.13894] [PMID: 30614070]
[45]
Esteghamati A, Larijani B, Aghajani MH, et al. Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Sci Rep 2017; 7(1): 13461.
[http://dx.doi.org/10.1038/s41598-017-13379-z] [PMID: 29044139]
[46]
Denig P, van Puijenbroek EP, Soliman N, Mol PGM, de Vries ST. Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. Pharmacoepidemiol Drug Saf 2019; 28(9): 1175-9.
[http://dx.doi.org/10.1002/pds.4839] [PMID: 31209934]
[47]
Inácio P, Gomes JJ, Airaksinen M, Cavaco A. Exploring sociodemographic and economic factors that promote adverse drug reactions reporting by patients. Health Policy 2018; 122(3): 263-8.
[http://dx.doi.org/10.1016/j.healthpol.2017.10.004] [PMID: 29128200]
[48]
Jacobs TG, Hilda Ampadu H, Hoekman J, Dodoo ANO, Mantel- Teeuwisse AK. The contribution of Ghanaian patients to the reporting of adverse drug reactions: A quantitative and qualitative study. BMC Public Health 2018; 18(1): 1384.
[http://dx.doi.org/10.1186/s12889-018-6285-9] [PMID: 30563498]
[49]
Khan A, Coffey M, Litterer KP, et al. Families as partners in hospital error and adverse event surveillance. JAMA Pediatr 2017; 171(4): 372-81.
[http://dx.doi.org/10.1001/jamapediatrics.2016.4812] [PMID: 28241211]
[50]
Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep 2019; 21(4): 21.
[http://dx.doi.org/10.1007/s11886-019-1107-y] [PMID: 30828746]
[51]
Harinstein L, Kalra D, Kortepeter CM, Muñoz MA, Wu E, Dal Pan GJ. Evaluation of postmarketing reports from industry-sponsored programs in drug safety surveillance. Drug Saf 2019; 42(5): 649-55.
[http://dx.doi.org/10.1007/s40264-018-0759-7] [PMID: 30569267]
[52]
Ifunanya NJ, Idzuinya OB, Okwuchukwu OV, et al. Evaluation of pregnancy outcomes among women with pregnancies complicated by diabetes mellitus in Abakaliki, south-east, Nigeria. J Diabetes Mellitus 2019; 9(3): 69-76.
[http://dx.doi.org/10.4236/jdm.2019.93008]
[53]
Magadla Y, Velaphi S, Moosa F. Incidence of hypoglycaemia in late preterm and term infants born to women with diabetes mellitus. SAJCH 2019; 13(2): 78-83.
[54]
Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: A global perspective. Lancet Diabetes Endocrinol 2016; 4(3): 275-85.
[http://dx.doi.org/10.1016/S2213-8587(15)00521-5] [PMID: 26857998]
[55]
Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type 2 diabetes: An effective, less-expensive option. JAMA 2017; 318(1): 23-4.
[http://dx.doi.org/10.1001/jama.2017.6939] [PMID: 28604935]
[56]
World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs - Insulins and Analogues Oslo, Norway 2020. Available from:https://www.whocc.no/atc_ddd_index/?code=A10 (Accessed:21 September 2020).
[57]
Corbin KD, Driscoll KA, Pratley RE, Smith SR, Maahs DM, Mayer-Davis EJ. Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms. Endocr Rev 2018; 39(5): 629-63.
[http://dx.doi.org/10.1210/er.2017-00191] [PMID: 30060120]
[58]
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669-701.
[http://dx.doi.org/10.2337/dci18-0033] [PMID: 30291106]
[59]
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 2019; 42(Suppl. 1): S13-28.
[http://dx.doi.org/10.2337/dc19-S002] [PMID: 30559228]
[60]
Howard-Thompson A, Khan M, Jones M, George CM. Type 2 diabetes mellitus: outpatient insulin management. Am Fam Physician 2018; 97(1): 29-37.
[PMID: 29365240]
[61]
Al Awadi FF, Echtay A, Al Arouj M, et al. Patterns of diabetes care among people with type 1 diabetes during ramadan: an international prospective study (DAR-MENA T1DM). Adv Ther 2020; 37(4): 1550-63.
[http://dx.doi.org/10.1007/s12325-020-01267-4] [PMID: 32144714]
[62]
Alluqmani WS, Alotaibi MM, Almalki WJ, et al. Exploring drug-related problems in diabetic patients during ramadan fasting in saudi arabia: a mixed-methods study. Int J Environ Res Public Health 2019; 16(3): E499.
[http://dx.doi.org/10.3390/ijerph16030499] [PMID: 30754675]
[63]
Hassanein M, Al Awadi FF, El Hadidy KES, et al. The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: An international prospective study (DAR-MENA T2DM). Diabetes Res Clin Pract 2019; 151: 275-84.
[http://dx.doi.org/10.1016/j.diabres.2019.02.020] [PMID: 30825560]
[64]
Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56(5): 399-403.
[http://dx.doi.org/10.1007/s002280000159] [PMID: 11009049]
[65]
Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med 2008; 121(6)(Suppl.): S9-S19.
[http://dx.doi.org/10.1016/j.amjmed.2008.03.022] [PMID: 18514090]
[66]
Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53(9): 787-800.
[http://dx.doi.org/10.1007/s40262-014-0165-y] [PMID: 25179915]

Rights & Permissions Print Cite
Article Metrics
33
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy